medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2006, Number 1

<< Back Next >>

Rev Invest Clin 2006; 58 (1)

The “Declaración de Acapulco”: a proposal to reduce incidence of diabetes in Mexico

Aguilar-Salinas CA, Gómez-Pérez FJ

Language: Spanish
References: 25
Page: 71-77
PDF size: 68.05 Kb.


ABSTRACT

Type 2 diabetes is the main health problem in Mexico. The growing number of cases, the high percentage of individuals with chronic complications and the treatment’s cost are among the explanations for the inability in the control of this disease. Diabetes prevention is most likely to reduce the rate of growth of this diabetes burden on our health system. At- risk individuals can be identified and several interventions have proved to be effective in decreasing diabetes incidence. Diabetes prevention related interventions can become a reality with the active participation of the government and society. Thus, a joint collaboration between the medical community, the government and society is needed to phase out the diabetes epidemic. Published diabetes prevention programs were reviewed and interventions feasible for Mexico were summarized in a document called “Declaración de Acapulco”. This paper was reviewed and approved by the Sociedad Mexicana de Nutrición y Endocrinología; additional endorsement was obtained from several Mexican and international societies and institutions. The manuscript describes several initiatives, which can be applied in schools, work places, primary health services and by the government. Some of these are focused on the general population; others are applicable to at-risk individuals. The “Declaración de Acapulco” is a-call-for-action position directed towards the whole society and designed to achieve effective diabetes prevention.


REFERENCES

  1. Rull JA, Aguilar-Salinas CA, Rojas R, Rios-Torres JM, Gómez-Pérez FJ, Olaiz G. Epidemiology of type 2 diabetes in Mexico. Arch Med Res 2005; 36: 188-96.

  2. Aguilar-Salinas CA, Velazquez Monroy O, Gómez-Pérez FJ, Gonzalez Chávez A, Lara Esqueda A, Molina Cuevas V, Rull-Rodrigo J, Tapia Conyer R for the ENSA 2000 Group. Characteristics of the patients with type 2 diabetes in Mexico: results from a large population-based, nation-wide survey. Diabetes Care 2003; 26: 2021-6.

  3. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Garcia E, Valles V, Ríos-Torres JM, Franco A, Olaiz G, Sepúlveda J, Rull JA Early onset type 2 diabetes in a Mexican, population-based, nation-wide survey: Am J Med 2002; 113: 569-74.

  4. Secretaría de Salud. Estadísticas de mortalidad en México: muertes registradas en el año 2003. Salud Pública de México 2005; 47: 171-88.

  5. Aguilar-Salinas CA. Promoción de la salud para la prevención de las enfermedades crónico degenerativas vinculadas con la alimentación y el estilo de vida. En: Salud Comunitaria y promoción de la salud. Editor. Mariano García Viveros 1999. ICEPSS Editores ISBN 84-89151-17-2. España

  6. Secretaría de Salud. Estadísticas de egresos hospitalarios del sector público del Sistema Nacional de Salud 2003. Salud Pública de México 2004; 46: 464-88.

  7. Arredondo A, Zúñiga A. Economic consequences of epidemiological changes in diabetes in middle income countries. Diabetes Care 2004; 27: 104-9.

  8. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Ríos-Torres JM, Franco A, Olaiz G, Rull JA, Sepúlveda J. High prevalence of the metabolic syndrome in Mexico. Arch Med Res 2004; 35: 76-81.

  9. Aguilar-Salinas CA, Mehta R, Rojas R, Gómez-Pérez FJ, Olaiz G, Rull JA. Management of the metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 diabetes: controversial issues. Current Diabetes Reviews 2005; 1: 145-58.

  10. Secretaría de Salud. Estadísticas de mortalidad en México: muertes registradas en el año 2000. Salud Pública de México 2002; 44: 266-83.

  11. Secretaría de Salud. Estadísticas de Mortalidad en México: muertes registradas en el año 2001. Salud Pública de México 2002; 47: 565-83.

  12. Secretaría de Salud. Estadísticas de mortalidad en México: muertes registradas en el año 2002. Salud Pública de México 2004; 46: 169-86.

  13. Bell C, Walley A, Froguel P. The genetics of human obesity. Nature Reviews 2005; 6: 221-35.

  14. Satterfiled D, Volansky M, Caspersen C, Engelgau M, Bowman B, Gregg E, Geiss L, Hosey G, May J, Vinicor F. Community based lifestyle interventions to prevent type 2 diabetes. Diabetes Care 2003; 26: 2643-52.

  15. Resnicow K. Reviewing the research on child and adolescent obesity: What do we know? In: Childhood obesity: Partnerships for research and prevention. Trowbridge F, Kibbe D (Eds.). ILSI Center for Health Promotion Monograph. Washington, DC: ILSI Press; 2002, pp. 11-30.

  16. Luepker R, Perry C, McKinlay S, Nader P, Parcel G, Stone E, et al. For the CATCH Collaborative Group. Outcomes of a field trial to improve children’s dietary patterns and physical activity. The child and adolescent trial for cardiovascular health (CATCH). JAMA 1996; 275: 768-76.

  17. McKenzie T, Li D, Derby C, Webber L, Luepker R, Cribb P. Maintenance of effects of the CATCH Physical Education Program: Results from the CATCH-ON Study. Health Educ Behav 2003; 30: 447-62.

  18. Hardeman W, Griffin S, Johnston M, Kinmonth AL, Wareham NJ. Interventions to prevent weight gain: a systematic review of psychological models and behaviour change methods. Int J Obes 2000; 24: 131-43.

  19. Coleman K, Tiller C, Sanchez J, Heath E, Sy O, Milliken G, Dzewaltowski D. Prevention of the epidemic increase in child risk of overweight in low-income schools. The El Paso Coordinated approach to child health. Arch Pediatr Adolesc Med 2005; 159: 217-24.

  20. Harris S, Zinman B. Primary prevention of type 2 diabetes in high-risk populations. Diabetes Care 2000; 23: 879-81.

  21. Diabetes Prevention Program Research Group: Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.

  22. Tuomilehto J, Lindstrom J, Eriksson J. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.

  23. Pawal R, Majumdar S, Johnson J, Varney J, McAlister F. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005; 28: 736-44.

  24. Australian Centre for Diabetes Strategies. National evidence based guidelines for the management of type 2 diabetes mellitus: Primary prevention, case detection and diagnosis. Publicado por National Health and Medical Research Council, 2001.

  25. Gahagan S, Silverstein J and the Committee on Native American Child Health and Section on Endocrinology. Prevention and Treatment of type 2 diabetes mellitus in children, with special emphasis on American Indian and Alaska native children. Pediatrics 2003; 112: e328-e347.




2020     |     www.medigraphic.com